Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Generex Biotechnology Corp. (GNBTQ) Message Board

Buildit, how many times does this need to happen?

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36566
(Total Views: 264)
Posted On: 11/24/2020 2:11:45 PM
Avatar
Posted By: tc2000chartreader
Re: Buildit #23842
Buildit, how many times does this need to happen? This brings into question the Bintai deal by just looking at their current business models, revenues and company net worth. We may have done a deal with a company that does not have the means to complete the trials, etc. So when hoops asked about SPAC, it brings up the authenticity of prior deals.
https://storage.googleapis.com/wzukusers/user...5_2019.pdf
Generex Biotechnology Announces Merger with Public Vehicle for Public
Trading of NuGenerex Immuno-Oncology
Quote:
Generex Biotechnology Corporation
(www.generex.com) (OTCQB:GNBT) today announced a merger transaction with a public
company that is DTC eligible and current with its SEC filings to serve as a vehicle for the
quotation of the common stock of its subsidiary NuGenerex Immuno-Oncology (NGIO) as
an independent, publicly traded company. Generex is in the process of finalizing its
annual report on Form 10-K, which will be filed in the coming days . The Form 10-K will
include the audited financial statements for the legal documentation and Super Form 8-
K filing for the merger of NGIO with the public vehicle. We expect that NuGenerex
Immuno-Oncology will be quoted on a public exchange by the end of November
, and the
1:4 shareholder dividend that was paid to Generex shareholders in February 2019 will be
converted into public shares shortly thereafter.



(1)
(0)




Generex Biotechnology Corp. (GNBTQ) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us